filings.toolsItem 4. Mine Safety Disclosures.
4K characters. Original on sec.gov · Markdown
Item 4. Mine Safety Disclosures.
Not Applicable.
Executive Officers of the Registrant (ages as of February 1, 2021)
All officers listed below serve at the pleasure of the Board of Directors. None of these officers was elected pursuant to any arrangement or understanding between the officer and any other person(s).
| Name | Age | Offices and Business Experience | ||||||
| Kenneth C. Frazier | 66 | Chairman, President and Chief Executive Officer (since December 2011) | ||||||
| Sanat Chattopadhyay | 61 | Executive Vice President and President, Merck Manufacturing Division (since March 2016) | ||||||
| Frank Clyburn | 56 | Executive Vice President, Chief Commercial Officer (since January 2019); President, Global Oncology Business Unit (October 2013-December 2018) | ||||||
| Robert M. Davis | 54 | Executive Vice President, Global Services, and Chief Financial Officer (since April 2016); Executive Vice President and Chief Financial Officer (April 2014-April 2016) | ||||||
| Richard R. DeLuca, Jr. | 58 | Executive Vice President and President, Merck Animal Health (since September 2011) | ||||||
| Michael W. Fleming | 62 | Senior Vice President, Chief Ethics and Compliance Officer (since March 2019); Senior Vice President, International Legal and Compliance (January 2017-March 2019); Vice President, International Legal and Compliance (July 2008-January 2017) | ||||||
| Julie L. Gerberding | 65 | Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health (since July 2016); Executive Vice President for Strategic Communications, Global Public Policy and Population Health (January 2015-July 2016) | ||||||
| Rita A. Karachun | 57 | Senior Vice President Finance - Global Controller (since March 2014) | ||||||
| Dean Li | 58 | President, Merck Research Laboratories (since January 2021); Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories (November 2017-January 2020); Vice President, Translational Medicine (March 2017-November 2017); Prior to that, Chief Scientific Officer and Associate Vice President, University of Utah Health Sciences | ||||||
| Steven C. Mizell | 60 | Executive Vice President, Chief Human Resources Officer (since December 2016); Executive Vice President, Human Resources, Monsanto Company (August 2011-December 2016) | ||||||
| Michael T. Nally | 45 | Executive Vice President, Chief Marketing Officer (since January 2019); President, Global Vaccines, Global Human Health (September 2016-January 2019); Managing Director, United Kingdom and Ireland, Global Human Health (January 2014-September 2016) | ||||||
| Jennifer Zachary | 43 | Executive Vice President, General Counsel and Corporate Secretary (since January 2020); Executive Vice President and General Counsel (April 2018-January 2020); Partner, Covington & Burling LLP (January 2013-March 2018) |
In February 2021, Merck announced that Kenneth C. Frazier, chairman and chief executive officer, will retire as chief executive officer, effective June 30, 2021. Mr. Frazier will continue to serve on Merck’s Board of Directors as executive chairman, for a transition period to be determined by the board. The Merck Board of Directors has unanimously elected Robert M. Davis, Merck’s current executive vice president, global services and chief financial officer, as chief executive officer, as well as a member of the board, effective July 1, 2021. Mr. Davis will become president of Merck, effective April 1, 2021, at which time the Company’s operating divisions—Human Health, Animal Health, Manufacturing, and Merck Research Laboratories—will begin reporting to Mr. Davis.
PART II
Previous: Item 3. Legal Proceedings. · Next: Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.